Bioactive glass-based surfaces induce differential gene expression profiling of osteoblasts.

The ability of Biosilicate® with two crystalline phases (BioS-2P) to drive osteoblast differentiation encourages the investigation of the cellular mechanisms involved in this process. Then, the aim of our study was to analyze the large-scale gene expression of osteoblasts grown on BioS-2P compared with Bioglass® 45S5 (45S5). Osteoblasts differentiated from rat bone marrow mesenchymal stem cells were cultured under osteogenic conditions on BioS-2P, 45S5 and polystyrene (control). After 10 days, the expression of 23,794 genes was analyzed using mRNA Sequencing and the data were validated by real-time PCR. The BioS-2P exhibited 5 genes upregulated and 3 downregulated compared with 45S5. Compared with control, BioS-2P upregulated 15 and downregulated 11 genes, while 45S5 upregulated 25 and downregulated 21 genes. Eight genes were commonly upregulated and 4 downregulated by both bioactive glasses. In conclusion, our results demonstrated that bioactive glasses affect the gene expression profiling of osteoblasts. Most of the regulated genes by both BioS-2P and 45S5 are associated with the process of mineralization highlighting their osteostimulation property that is, at least in part, derived from the ability to modulate the intracellular machinery to promote osteoblast genotype expression. © 2016 Wiley Periodicals, Inc. J Biomed Mater Res Part A: 105A: 419-423, 2017.

Toxocara canis and the allergic process.

The protective effect of infectious agents against allergic reactions has been thoroughly investigated. Current studies have demonstrated the ability of some helminths to modulate the immune response of infected hosts. The objective of the present study was to investigate the relationship between Toxocara canis infection and the development of an allergic response in mice immunised with ovalbumin (OVA). We determined the total and differential blood and bronchoalveolar lavage fluid cells using BALB/c mice as a model. To this end, the levels of interleukin (IL)-4, IL-5 and IL-10 and anti-OVA-IgE were measured using an ELISA. The inflammatory process in the lungs was observed using histology slides stained with haematoxylin and eosin. The results showed an increase in the total number of leukocytes and eosinophils in the blood of infected and immunised animals at 18 days after infection. We observed a slight lymphocytic inflammatory infiltrate in the portal space in all infected mice. Anti-OVA-IgE levels were detected in smaller proportions in the plasma of immunised and infected mice compared with mice that were only infected. Therefore, we concluded that T. canis potentiates inflammation in the lungs in response to OVA, although anti-OVA-IgE levels suggest a potential reduction of the inflammatory process through this mechanism.

Toxocara canis and the allergic process

The protective effect of infectious agents against allergic reactions has been thoroughly investigated. Current studies have demonstrated the ability of some helminths to modulate the immune response of infected hosts. The objective of the present study was to investigate the relationship between Toxocara canis infection and the development of an allergic response in mice immunised with ovalbumin (OVA). We determined the total and differential blood and bronchoalveolar lavage fluid cells using BALB/c mice as a model. To this end, the levels of interleukin (IL)-4, IL-5 and IL-10 and anti-OVA-IgE were measured using an ELISA. The inflammatory process in the lungs was observed using histology slides stained with haematoxylin and eosin. The results showed an increase in the total number of leukocytes and eosinophils in the blood of infected and immunised animals at 18 days after infection. We observed a slight lymphocytic inflammatory infiltrate in the portal space in all infected mice. Anti-OVA-IgE levels were detected in smaller proportions in the plasma of immunised and infected mice compared with mice that were only infected. Therefore, we concluded that T. canis potentiates inflammation in the lungs in response to OVA, although anti-OVA-IgE levels suggest a potential reduction of the inflammatory process through this mechanism.

A clinical, randomized, controlled study on the use of desensitizing agents during tooth bleaching.

OBJECTIVES: To evaluate the efficacy of experimental proposals of desensitizing agents during tooth bleaching. METHODS: 140 participants without tooth sensitivity (TS) received 16% carbamide peroxide (14 days-04 h each) (T1) or 35% hydrogen peroxide (single session-45 min) (T2). Participants used concomitantly (10 per group): desensitizing dentifrices (D1-experimental bioactive glass-ceramic; D2-commercial potassium nitrate; D3-commercial calcium and sodium phosphosilicate) in-home, daily and, desensitizing pastes (D4-experimental bioactive glass-ceramic; D5-experimental Bioglass type 45S5; D6-commercial calcium phosphate), in-office, immediately after the treatment and more 4 times. Participants in the control group did not use any desensitizing agent. We assessed TS with Visual Analogue Scale. Assessment point 1 was immediately after the first participant's exposure to the treatments; and points 2, 3, 4, and 5 were every 72 h along the period of the study. Two-way ANOVA (considering time and desensitizing as factors) and post-hoc Tukey test (α=0.05) analyzed the data. RESULTS: In the control group treated with 35% hydrogen peroxide, TS increased significantly on assessment points 1 and 2. The participants who used a 5% potassium nitrate dentifrice and in-office experimental pastes did not experience TS because of the 35% in-office bleaching treatment. CONCLUSIONS: TS caused by 35% hydrogen peroxide in-office tooth bleaching was controlled by experimental products prepared as pastes D4-experimental bioactive glass-ceramic and D5-experimental Bioglass type 45S5, but not by D1-experimental dentifrice containing bioactive glass-ceramic. CLINICAL SIGNIFICANCE: There is no a gold standard protocol for TS caused by tooth bleaching. The study of novel desensitizing agents that can obliterate the dentinal tubules in a faster-acting and long-lasting way may help meet this clinical need.

Porous bioactive scaffolds: characterization and biological performance in a model of tibial bone defect in rats.

The aim of this study was to evaluate the effects of highly porous Biosilicate(®) scaffolds on bone healing in a tibial bone defect model in rats by means of histological evaluation (histopathological and immunohistochemistry analysis) of the bone callus and the systemic inflammatory response (immunoenzymatic assay). Eighty Wistar rats (12 weeks-old, weighing±300 g) were randomly divided into 2 groups (n=10 per experimental group, per time point): control group and Biosilicate® group (BG). Each group was euthanized 3, 7, 14 and 21 days post-surgery. Histological findings revealed a similar inflammatory response in both experimental groups, 3 and 7 days post-surgery. During the experimental periods (3-21 days post-surgery), it was observed that the biomaterial degradation, mainly in the periphery region, provided the development of the newly formed bone into the scaffolds. Immunohistochemistry analysis demonstrated that the Biosilicate® scaffolds stimulated cyclooxygenase-2, vascular endothelial growth factor and runt-related transcription factor 2 expression. Furthermore, in the immunoenzymatic assay, BG presented no difference in the level of tumor necrosis factor alpha in all experimental periods. Still, BG showed a higher level of interleukin 4 after 14 days post-implantation and a lower level of interleukin 10 in 21 days post-surgery. Our results demonstrated that Biosilicate® scaffolds can contribute for bone formation through a suitable architecture and by stimulating the synthesis of markers related to the bone repair.

Histopathological, cytotoxicity and genotoxicity evaluation of Biosilicate® glass-ceramic scaffolds.

This study evaluated the biocompatibility of Biosilicate® scaffolds by means of histopathological, cytotoxicity, and genotoxicity analysis. The histopathologic analysis of the biomaterial was performed using 65 male rats, distributed into the groups: control and Biosilicate®, evaluated at 7, 15, 30, 45, and 60 days after implantation. The cytotoxicity analysis was performed by the methyl thiazolyl tetrazolium (MTT) assay, with various concentrations of extracts from the biomaterial in culture of osteoblasts and fibroblasts after 24, 72, and 120 h. The genotoxicity analysis (comet assay) was performed in osteoblasts and fibroblasts after contact with the biomaterial during 24, 72, and 96 h. In the histopathology analysis, we observed a foreign body reaction, characterized by the presence of granulation tissue after 7 days of implantation of the biomaterial, and fibrosis connective tissue and multinucleated giant cells for longer periods. In the cytotoxicity analysis, extracts from the biomaterial did not inhibit the proliferation of osteoblasts and fibroblasts, and relatively low concentrations (12.5% and 25%) stimulated the proliferation of both cell types after 72 and 120 h. The analysis of genotoxicity showed that Biosilicate® did not induce DNA damage in both lineages tested in all periods. The results showed that the Biosilicate® scaffolds present in vivo and in vitro biocompatibility.

Effects of biosilicate and bioglass 45S5 on tibial bone consolidation on rats: a biomechanical and a histological study.

The purpose of this study was to investigate the effects of Bioglass 45S5 and Biosilicate, on bone defects inflicted on the tibia of rats. Fifty male Wistar rats were used in this study, and divided into five groups, including a control group, to test Biosilicate and Bioglass materials of two different particle sizes (180-212 microm or 300-355 microm). All animals were sacrificed 15 days after surgery. No significant differences (P > 0.05) were found when values for Maximal load, Energy Absorption and Structural Stiffness were compared among the groups. Histopathological evaluation revealed osteogenic activity in the bone defect for the control group. Nevertheless, it seems that the amount of fully formed bone was higher in specimens treated with Biosilicate (granulometry 300-355 microm) when compared to the control group. The same picture occurred regarding Biosilicate with granulometry 180-212 microm. Morphometric findings for bone area results (%) showed no statistically significant differences (P > 0.05) among the groups. Taken together, such findings suggest that, Biosilicate exerts more osteogenic activity when compared to Bioglass under subjective histopathological analysis.